US OptionsDetailed Quotes
NRIX250117C12500
- 0.00
- 0.000.00%
15min DelayClose Jan 6 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover260.60%IV-34.96%PremiumJan 17, 2025Expiry Date6.72Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8821Delta0.0229Gamma2.61Leverage Ratio-0.0800Theta0.0029Rho2.31Eff Leverage0.0065Vega
Nurix Therapeutics Stock Discussion
Sign in to post a comment
$Nurix Therapeutics (NRIX.US)$
NRIX exhibits a moderately high risk level primarily due to its financial underperformance, demonstrated by substantial net losses and negative free cash flow, indicating financial instability. Additionally, its PE ratio is negative, reflecting market uncertainties regarding future profitability. Despite positive news catalysts, the absence of profitability and the high volatility in the biotechnology sector compounds the riskiness of the stock. Recent positive anal...
NRIX exhibits a moderately high risk level primarily due to its financial underperformance, demonstrated by substantial net losses and negative free cash flow, indicating financial instability. Additionally, its PE ratio is negative, reflecting market uncertainties regarding future profitability. Despite positive news catalysts, the absence of profitability and the high volatility in the biotechnology sector compounds the riskiness of the stock. Recent positive anal...
$Nurix Therapeutics (NRIX.US)$ Chif Lao BUYERS Sell now +💰💰💰💰💰💰💰💰💰🤗🤗🤗
$Nurix Therapeutics (NRIX.US)$ Nurix Therapeutics Inc - Commenced an Underwritten Public Offering of $125 Mln of Its Common Stock
2
$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
11
1
Investors may believe the company's poor revenue performance won't improve, causing a low P/S ratio. The company's future revenue growth is expected to be weaker than the industry average, causing discomfort among shareholders.
1
Investors remain skeptical of Nurix Therapeutics' future despite strong performance, with its forecasted growth rate much lower than the industry's 235%. Current P/S ratio hints that expected growth may not justify a higher P/S, needing a turnaround to satisfy investor sentiment.
$Nurix Therapeutics (NRIX.US)$ Nurix Therapeutics (NASDAQ:NRIX) said that the FDA has placed a partial clinical hold on a Phase 1 study of its drug NX-2127 in the treatment of B-cell malignancies as the company’s shifts to a different manufacturing process for the product.
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company sai...
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company sai...
1
No comment yet
EmotionOutOfEquation : Already 500% current year where is yearly bottom of strong buy potential
EmotionOutOfEquation : Time to make separate watchlist of strong buys so get better cost price for less red days